Literature DB >> 23047642

Role of parathyroidectomy on anemia control and erythropoiesis-stimulating agent need in secondary hyperparathyroidism of chronic kidney disease. A retrospective study in 30 hemodialysis patients.

Giovanni Conzo, Alessandra Perna, Cristina Della Pietra, Daniela Esposito, Anna Nunziata, Antonietta Palazzo, Alessandra Pizza, Ersilia Satta, Valerio Sciascia, Luigi Santini.   

Abstract

BACKGROUND: Parathyroidectomy (Ptx) ameliorates anemia (A) and reduces postoperative erythropoiesis-stimulating agent (ESA) requirement. The authors retrospectively evaluated the effects of successful Ptx on chronic A and ESA need in 30 2HPT patients.
METHODS: From 2004 to 2009,30 anemic hemodialysis (HD) patients, affected by severe 2HPT, underwent Ptx -15 total parathyroidectomy (TP) and 15 TP + subcutaneous autoimplantation (TPai). Patients were evaluated for iPTH, hemoglobin (Hb) levels, erythrocyte count, hematocrit and erythropoietin dosing before and at 6, and 12 months after surgery.
RESULTS: In every case, Ptx achieved a dramatic reduction of iPTH levels. In 26/30 cases(86.6%) an improvement of Hb levels was observed,and 27/30 (90%) patients did not need postoperative ESA treatment,irrespective of the type of surgical procedure carried out (TP or TPai).
CONCLUSIONS: Successful Ptx for 2HPT of CKD determined a considerable improvement of A,reducing exogenous ESA need.In 2HPT of HD patients A is a secondary indication to surgical treatment,but we propose that this condition should be taken into more careful account, given the high costs of ESA therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23047642

Source DB:  PubMed          Journal:  Ann Ital Chir        ISSN: 0003-469X            Impact factor:   0.766


  6 in total

1.  Association of Increased Serum Leptin with Ameliorated Anemia and Malnutrition in Stage 5 Chronic Kidney Disease Patients after Parathyroidectomy.

Authors:  Yao Jiang; Jingjing Zhang; Yanggang Yuan; Xiaoming Zha; Changying Xing; Chong Shen; Zhixiang Shen; Chao Qin; Ming Zeng; Guang Yang; Huijuan Mao; Bo Zhang; Xiangbao Yu; Bin Sun; Chun Ouyang; Xueqiang Xu; Yifei Ge; Jing Wang; Lina Zhang; Chen Cheng; Caixia Yin; Jing Zhang; Huimin Chen; Haoyang Ma; Ningning Wang
Journal:  Sci Rep       Date:  2016-06-16       Impact factor: 4.379

2.  Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study.

Authors:  Motoko Tanaka; Kazuki Yoshida; Shingo Fukuma; Kazuko Ito; Kazutaka Matsushita; Masafumi Fukagawa; Shunichi Fukuhara; Tadao Akizawa
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

Review 3.  Effect of peritoneal dialysis versus hemodialysis on renal anemia in renal in end-stage disease patients: a meta-analysis.

Authors:  Wan-Ning Wang; Wen-Long Zhang; Tao Sun; Fu-Zhe Ma; Sensen Su; Zhong-Gao Xu
Journal:  Ren Fail       Date:  2016-11-17       Impact factor: 2.606

4.  Impact of parathyroidectomy among nondiabetic hemodialysis patients with severe hyperparathyroidism.

Authors:  Qing-Xiu Huang; Jie Pang; Chuan-Ke Shi; Xiao-Wen Huang; Xiao-Fang Chen; Yan-Feng Luo; Hai-Wen An; Jian-Lin Jian; Linna Liu; Yan-Lin Li
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

5.  Impact of parathyroidectomy on cardiovascular outcomes and survival in chronic hemodialysis patients with secondary hyperparathyroidism. A retrospective study of 50 cases prior to the calcimimetics era.

Authors:  Giovanni Conzo; Alessandra F Perna; Vincenzo Savica; Antonietta Palazzo; Cristina Della Pietra; Diego Ingrosso; Ersilia Satta; Giovambattista Capasso; Luigi Santini; Giovanni Docimo
Journal:  BMC Surg       Date:  2013-10-08       Impact factor: 2.102

Review 6.  Protein Quality Control in the Endoplasmic Reticulum and Cancer.

Authors:  Hye Won Moon; Hye Gyeong Han; Young Joo Jeon
Journal:  Int J Mol Sci       Date:  2018-10-03       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.